Form 4: Syndax Pharmaceuticals Director Keith Katkin Reports Changes in Beneficial Ownership

Director Keith Katkin reports acquisition and disposal of Syndax Pharmaceuticals stock.

Summary

• On February 5, 2025, Keith Katkin, a director of Syndax Pharmaceuticals Inc., reported changes in beneficial ownership of the company's stock.
• Katkin acquired 25,000 shares of common stock through an award of Restricted Stock Units (RSUs) at a price of $0.
• Katkin disposed of 90,000 shares of common stock.
• Following these transactions, Katkin directly owns 90,000 shares of Syndax Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without expressing an opinion on the company's performance or future prospects. The acquisition and disposal offset each other to some extent.

Positives

• The acquisition of 25,000 shares via RSUs could be seen as a positive sign of confidence in the company's future.

Negatives

• The disposal of 90,000 shares could be interpreted negatively, although the reason for the disposal is not specified.

Risks

• The vesting conditions of the RSUs (separation from service, death, disability, or change in control) introduce uncertainty regarding the actual delivery of the shares.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The market often interprets these filings as signals of management's sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates